by Jay Bitkower | Jun 13, 2022 | ACKC Investigates
This story begins in October 1996 on Wilbur Earl Tennant’s farm outside of Parkersburg, WV, a town of 30,000 people located across the Ohio River from Ohio. For decades, Earl raised beef cattle on his 300-acre spread. For the last two years, he noticed with alarm that...
by Jay Bitkower | Jun 13, 2022 | ACKC Investigates
It was 2014. Michael Hickey wanted to sleep at night. He had uncovered a terrible truth that meant accusing the biggest employer, Saint-Gobain Performance Plastics, in the small, upstate New York town of Hoosick Falls, of polluting their drinking water. His friends...
by Jay Bitkower | Jun 1, 2022 | Kidney Cancer News
Editor’s Note: The following is an essay by Stephen J. Gould, a leading evolutionary biologist on the faculties of Harvard and New York University. In 1982, he was diagnosed with abdominal mesothelioma and found out through his research into the disease that the...
by Jay Bitkower | Aug 28, 2020 | Therapeutics Updates
From October 2014 through June 2017, Bristol-Myers Squibb sponsored a Stage III trial, called CheckMate 214 (NCT02231749 on clinicaltrials.gov), testing the combination of therapies nivolumab (Opdivo) and ipilimumab (Yervoy) against sunitnib (Sutent) in...
by Jay Bitkower | Aug 25, 2020 | Therapeutics Updates
Introduction The FDA approved the combination therapy avelumab and axitinib for first-line treatment of metastatic kidney cancer patients on May 14, 2019 based on the results of a Phase III trial, Javelin 101 Renal, led by Toni Choueiri of Dana Farber Institute,...
